000			02899cam a2200349 a 4500
003			EG-GiCUC
005			20250223032455.0
008			191207s2019 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.19.05.M.Sc.2019.En.O
100	0		_aEnas Nagi Gaafar
245	1	0	_aOutcome of pediatric patients with rhabdomyosarcoma at National Cancer Institute, Egypt / _cEnas Nagi Gaafar ; Supervised Hossam Eldeen Ahmed Abdelmonem , Amr Abdalla Salem , Ebraheem Abdalrahman Ebraheem
246	1	5	_aنتائج علاج الأطفال المرضى بالساركوما العضلية بالمعهد القومى الأورام. مصر
260			_aCairo : _bEnas Nagi Gaafar , _c2019
300			_a105 P. : _bcharts , facimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
520			_aBackground: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in infants and children. It is the third most common solid tumor in children after neuroblastoma and Wilms tumor, making up 10-15% of all solid pediatric tumors. RMS incidence follows a bimodal age pattern. The first window of increased incidence, which accounts for more than 50% of cases, occurs in the first decade. This period peaks at a median of 2 years of age and consists mainly of embryonal (E-RMS) or botryoid RMS (B-RMS). The second peak occurs during adolescence and more commonly consists of alveolar RMS (A-RMS).Objectives: - To assess OS, EFS and DFS with a minimum one year follow up from the last patient.To identify the relationships between different demographic variables with OS, EFS and DFS to identify relevant prognostic factors. To detect relationships between survival rates and different modalities of local control (surgery, radiation therapy or both). Patients and methods: This is a retrospective study to evaluate treatment outcome of patients below 18 years of age, newly diagnosed with rhabdomyosarcoma who were treated at pediatric oncology department, National Cancer Institute (NCI), Cairo University, Egypt during the period from January 2012 to December 2016 Results: 54 pediatric patients with RMS with age ranging from 7 months to 17 years (median age 5 years) were studied. The median follow up period ranged with a median of one year for the last patient
530			_aIssued also as CD
653		4	_aCombined modality therapy
653		4	_aIRS risk grouping
653		4	_aRhabdomyosarcoma in pediatric patients
700	0		_aAmr Abdalla Salem , _eSupervisor
700	0		_aEbraheem Abdalrahman Ebraheem , _eSupervisor
700	0		_aHossam Eldeen Ahmed Abdelmonem , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c75696 _d75696